In 3Q15, Celgene’s (CELG) oncology drug Abraxane managed to earn revenues of about $229.9 million, an 8.3% rise from the $212.2 million earned in 3Q14. Based on the drug’s performance, Celgene has ...

– Data from Pre-Clinical Studies to Be Presented at 101 st Annual Meeting of the American Association for Cancer Research – “This model was developed to increase our understanding of hard to treat ...

Approval Based on Significantly Improved Overall Response Rates in all Patients Regardless of Histology Adds a New Therapeutic Option for Patients with Lung Cancer, the Leading Cause of Cancer Deaths ...

Abraxane plus gemcitabine was superior to gemcitabine alone with statistically significant and clinically meaningful results across primary and key secondary endpoints and patient subgroups Oral ...

Pomalyst and Abraxane are the next largest revenue generators for Celgene (CELG) after Revlimid. In the United States, Pomalyst is used to treat multiple myeloma patients who have gone through at ...

Pancreatic cancer is an aggressive, hard-to-treat disease, especially once it spreads outside the pancreas. Unfortunately, about 80 percent of pancreatic tumors are diagnosed at stage 4. Because of ...

Abraxane, a cancer chemotherapy made by Celgene, slowed tumor growth and cut the risk of death in patients with advanced pancreatic cancer, according to results that will be presented at a conference ...

Abraxane approval for pancreatic cancer will boost Celgene's top-line. FDA approval Earlier this month, the FDA approved Celgene's supplemental New Drug Application, or sNDA, for Abraxane as ...

CHICAGO, May 26 (Reuters) - Abraxane, a new cancer drug designed to be less toxic than standard chemotherapy, did a better job of keeping cancer at bay in women whose breast cancer had spread, U.S.

Dec. 8, 2003 (San Antonio) — Abraxane (formerly ABI-007) is an old drug in a new package that promises to make chemotherapy less toxic and more effective for women with metastatic breast cancer. The ...